Inhibition of Spi1 alleviates doxorubicin-induced myocardial injury by suppressing YTHDF2-mediated PI3K/AKT/mTOR signaling
International Immunopharmacology · 2026-01 · 168 · 115950
DOI: 10.1016/j.intimp.2025.115950 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-01. Verfasst von Xinyi Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Myocarditis, RNA-Binding Proteins, Proto-Oncogene Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Shanghai Pudong New Area Health Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cardiovascular diseases have long posed a significant threat to public health. Among them, myocarditis is a major category of cardiovascular disorders that is characterized by high mortality during its acute phase, necessitating urgent medical attention. This study aims to explore the therapeutic effects and underlying mechanisms of Spi1-mediated gene regulation in chemotherapy induced cardiomyopathy. To validate our findings, we employed bioinformatics analysis methods and established myocarditis models using the chemotherapeutic drug doxorubicin in both cellular and animal models. Our results demonstrated that the inhibition of Spi1 significantly suppressed inflammatory factor expression in H9C2 rat cardiomyocytes. Furthermore, in C57BL/6 mouse model, Spi1 inhibition was shown to improve cardiac function and alleviate both myocardial inflammation and fibrosis in mice with doxorubicin-induced myocarditis. Mechanistic investigations revealed that Spi1 suppression altered the expression of genes associated with immune response, cell differentiation and proliferation. Notably, Spi1 modulates the expression of YTHDF2, thereby influencing the PI3K/AKT/mTOR signaling pathway and subsequently regulating the inflammatory response. Collectively, these findings suggest that Spi1 plays a pivotal role in doxorubicin-induced myocarditis by mitigating inflammatory responses and myocardial injury through the regulation of YTHDF2 and the PI3K/AKT/mTOR signaling pathways, offering a promising therapeutic target for the treatment of myocarditis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.
- Department of Clinical Laboratory, Gongli Hospital of Shanghai Pudong New Area, Shanghai, China.
- Postgraduate Training Base at Shanghai Gongli Hospital, Ningxia Medical University, Shanghai, China.
- Hospital Department, Shanghai University of Medicine and Health Sciences Affiliated to Zhoupu Hospital, Shanghai, China. Electronic address: tianzhaoxufan@163.com.
- School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China; Department of Clinical Laboratory, Gongli Hospital of Shanghai Pudong New Area, Shanghai, China. Electron…
Förderung
- Shanghai Pudong New Area Health Commission
- National Natural Science Foundation of China
Zitieren
APA
Li, X., Song, H., Yuan, Y., Jiang, N., Duan, W., Xu, T., Liu, C., & Liu, X. (2026). Inhibition of Spi1 alleviates doxorubicin-induced myocardial injury by suppressing YTHDF2-mediated PI3K/AKT/mTOR signaling. International Immunopharmacology, 168, 115950. https://doi.org/10.1016/j.intimp.2025.115950
Vancouver
Li X, Song H, Yuan Y, Jiang N, Duan W, Xu T, et al. Inhibition of Spi1 alleviates doxorubicin-induced myocardial injury by suppressing YTHDF2-mediated PI3K/AKT/mTOR signaling. International Immunopharmacology. 2026;168:115950. doi:10.1016/j.intimp.2025.115950
BibTeX
@article{Li2026,
author = {Li, Xinyi and Song, Hui and Yuan, Yiwen and Jiang, Na and Duan, Wei and Xu, Tianzhao and Liu, Chang and Liu, Xinghui},
title = {Inhibition of Spi1 alleviates doxorubicin-induced myocardial injury by suppressing YTHDF2-mediated PI3K/AKT/mTOR signaling},
journal = {International Immunopharmacology},
year = {2026},
volume = {168},
pages = {115950},
doi = {10.1016/j.intimp.2025.115950}
}
EUVIMED